Clinical Trial

Digital Heart Rate Variability Biofeedback Intervention for First Episode Psychosis

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The objective of the current study is to assess the impact of a five-week digital heart rate variability biofeedback (HRV-B) intervention or music listening on the well-being of first episode psychosis patients. Heart rate variability (HRV) is a measure of how an individual's heart rate can adapt to a changing environment and mental and physiological challenges. It has been well established that HRV can be regulated through actions such as slow breathing and meditation. HRV Biofeedback (HRV-B) involves breathing at a specific frequency, usually around 6 breaths per minute, which has been shown to maximize HRV. Research has shown that HRV-B interventions improved mental health symptoms in various populations including individuals at clinical high risk for psychosis.
Trial Details
NCT Number NCT07628699
Lead Sponsor The University of Hong Kong
Conditions First Episode Psychosis (FEP)
Enrollment 80 participants
Start Date 2026-06-01
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-05